Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) non-small cell lung cancer (NSCLC)

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2024
This article has no abstract
Epistemonikos ID: 328d5c8e3148021da1df35555135ea29159f70c9
First added on: Feb 19, 2025